All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Boston Therapeutics Inc., of Manchester, N.H., said it received institutional review board approval to start a phase II study of BTI-320 (formerly PAZ320), a nonsystemic chewable complex carbohydrate-based compound, in the U.S.